Theravance Biopharma Inc (TBPH) USD0.00001

Sell:$8.92Buy:$8.94$0.11 (1.22%)

NASDAQ:0.93%
Prices delayed by at least 15 minutes
Sell:$8.92
Buy:$8.94
Change:$0.11 (1.22%)
Prices delayed by at least 15 minutes
Sell:$8.92
Buy:$8.94
Change:$0.11 (1.22%)
Prices delayed by at least 15 minutes

Company Information

About this company

Theravance Biopharma, Inc. is a biopharmaceutical company primarily focused on the development, and commercialization of medicines. Its product, YUPELRI (revefenacin) inhalation solution is indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). YUPELRI is a prescription medicine used to treat COPD, a long-term lung disease that includes chronic bronchitis, emphysema, or both. YUPELRI is an anticholinergic medicine, which helps the muscles around the airway in lungs stay relaxed to prevent symptoms, such as wheezing, shortness of breath, and others. Ampreloxetine, its late-stage investigational norepinephrine reuptake inhibitor in development for symptomatic neurogenic orthostatic hypotension.

Key people

Rick E. Winningham
Chairman of the Board, Chief Executive Officer
Aziz Sawaf
Chief Financial Officer, Senior Vice President
Brett A. Grimaud
Senior Vice President, General Counsel, Secretary
Rhonda F. Farnum
Senior Vice President - Commercial and Medical Affairs, Chief Business Officer
Aine Miller
Senior Vice President - Development and Head of Ireland Office
Dean Jonathan Mitchell
Lead Independent Director
Laurie Smaldone Alsup
Independent Director
Eran Broshy
Independent Director
Jeremy T. Grant
Independent Director
Susannah Gray
Independent Director
Click to see more

Key facts

  • EPIC
    -
  • Location
    Cayman Islands
  • Sector
    Healthcare
  • Industry
    Biotechnology & Drugs
  • ISIN
    KYG8807B1068
  • Market cap
    $448.47m
  • Employees
    99
  • Shares in issue
    49.17m
  • Exchange
    NASDAQ
  • Index

Data policy - All information should be used for indicative purposes only. You should independently check data before making any investment decision. HL cannot guarantee that the data is accurate or complete, and accepts no responsibility for how it may be used. Overview data is sourced from Refinitiv.